Dall P, et al. - Researchers here report the subgroup results from a large observational study of patients with early breast cancer (EBC) receiving trastuzumab-containing (neo)adjuvant therapy. Based on the findings, they recommend considering trastuzumab plus chemotherapy as the preferred option for all patients with HER2-positive EBC with an indication for adjuvant treatment. However, an alternative treatment approach will be required for a limited proportion of patients, either because of contraindications or the patient’s preference. Trastuzumab monotherapy, eventually combined with endocrine agents, may be a reasonable option, in these selected patients, granting favorable long-term outcomes by addressing the high-risk profile associated with HER2-positive disease.